Model-informed COVID-19 vaccine prioritization strategies by age and serostatus
Open accessPublished version of a preprint
The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Limited initial supply of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine raises the question of how to prioritize available doses. We used a mathematical model to compare five age-stratified prioritization strategies. A highly effective transmission-blocking vaccine prioritized to adults ages 20 to 49 years minimized cumulative incidence, but mortality and years of life lost were minimized in most scenarios when the vaccine was prioritized to adults greater than 60 years old. Use of individual-level serological tests to redirect doses to seronegative individuals improved the marginal impact of each dose while potentially reducing existing inequities in COVID-19 impact. Although maximum impact prioritization strategies were broadly consistent across countries, transmission rates, vaccination rollout speeds, and estimates of naturally acquired immunity, this framework can be used to compare impacts of prioritization strategies across contexts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Impacts of vaccine prioritization strategies on mortality and infections. (A) Distribution of vaccines for five prioritization strategies: under 20 years, adults 20 to 49 years, adults 20+ years, adults 60+ years, and all ages. (B, C, F, and G) Example simulation curves show [(B) and (C)] percentage of the total population infected over time and [(F) and (G)] cumulative mortality for no vaccines (gray dashed lines) and for five different prioritization strategies [colored lines matching (A)], with [(B) and (F)] 10% and [(C) and (G)] 30% vaccine supply. (D, E, H, and I) Summary curves show percent reductions in [(D) and (E)] infections and [(H) and (I)] deaths in comparison to an unmitigated outbreak for vaccine supplies between 1 and 50% after 365 days of simulation. Squares and diamonds show how the outputs from single simulations [(F) and (G)] correspond to points in summary curves (H). Gray shading indicates the period during which vaccine is being rolled out at 0.2% of total population per day. Black dots indicate break points at which prioritized demographic groups have been 70% vaccinated, after which vaccines are distributed without prioritization. These simulations assume contact patterns and demographics of the United States (38, 53) and an all-or-nothing, transmission-blocking vaccine with 90% vaccine efficacy and R0 = 1.5 (scenario 2) and R0 = 1.15 (scenario 1).](https://figures.cochat.ai/paper-figures/040af1c419fe4105805e757ba6eecdfa/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-1.jpg)
![Fig. 2 Mortality-minimizing vaccine prioritization strategies across reproductive numbers R0 and countries. (A to E) Heatmaps show the prioritization strategies that result in maximum reduction of mortality for varying values of [(A) and (B)] the basic reproductive number R0 and [(C), (D), and (E)] across nine countries, for vaccine supplies between 1 and 50% of the total population, for an all-or-nothing and transmission-blocking vaccine, 90% vaccine efficacy. [(A) and (B)] Contact patterns and demographics of the United States (38, 53). [(C), (D), and (E)] Contact patterns and demographics of POL, Poland; ZAF, South Africa; CHN, China; BRA, Brazil; ZWE, Zimbabwe; ESP, Spain; IND, India; USA, United States of America; and BEL, Belgium, with R0 and rollout speeds as indicated.](https://figures.cochat.ai/paper-figures/3232e6d2c98d4491b422e996e35f7beb/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-2.jpg)
![Fig. 3 Effects of age-dependent vaccine efficacy on the impacts of prioritization strategies. (A) Diagram of hypothetical age-dependent vaccine efficacy shows decrease from 90% baseline efficacy to 50% efficacy among individuals aged 80+ years, beginning at age 60 (dashed line). (B and C) Percent reduction in deaths in comparison with an unmitigated outbreak for transmission-blocking all-or-nothing vaccines with either constant 90% efficacy for all age groups (solid lines) or age-dependent efficacy shown in (A) (dashed lines), covering scenario 1 [0.2% rollout per day, R0 = 1.15; (B)] and scenario 2 [0.2% rollout per day, R0 = 1.5 (C)]. Black dots indicate break points at which prioritized demographic groups have been 70% vaccinated, after which vaccines are distributed without prioritization. Shown are contact patterns and demographics of the United States (38, 53); all-or-nothing and transmission-blocking vaccine.](https://figures.cochat.ai/paper-figures/85e54e74290b4a1b82ec5b49b5f8d03f/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-3.jpg)
![Fig. 4 Effects of existing seropositivity on the impacts of prioritization strategies. (A to C) Percent reductions in (A) infections, (B) deaths, and (C) years of life lost (YLL) for prioritization strategies when existing age-stratified seroprevalence is incorporated [August 2020 estimates for New York City; mean seroprevalence 26.9% (28)]. Plots show reductions for scenario 2 (0.2% rollout per day, R0 = 1.5) when vaccines are given to all individuals (solid lines) or to only seronegatives (dashed lines), inclusive of 96% serotest sensitivity, 99% specificity (54), and approximately 3 months of seroreversion (supplementary materials, materials and methods) (29). Shown are U.S. contact patterns and demographics (38, 53), all-or-nothing and transmission-blocking vaccine with 90% vaccine efficacy. Lower and higher seroprevalence examples are provided in figs. S12 and S13, respectively.](https://figures.cochat.ai/paper-figures/4122f4138dc44271af1ce6fd7d40abb0/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Vaccination alone is not expected to be able to control the spread of the infection, and a carefully planned vaccination campaign25,26 needs to be coordinated with continued implementation of NPIs27 until sufficient coverage is reached to make the case fatality rate (CFR) similar to that of seasonal influenza.”
From Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy (2021) · cites this paper as [25]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656
COVID-19 and Racial/Ethnic Disparities
Webb Hooper, M., Nápoles, A. M., & Pérez-Stable, E. J. (2020) · JAMA · doi:10.1001/jama.2020.8598 · Cited by 2,047 · cited 1×
“However, other factors correlate with disease outcomes, such as treatment and healthcare access and comorbidities, which may correlate with factors like rural vs urban location, socioeconomic status, sex ( 41, 42 ), and race and ethnicity ( 43 ), that are not accounted for in this study.”
Age-dependent effects in the transmission and control of COVID-19 epidemics
Davies, N. G., Klepac, P., Liu, Y., Prem, K., Jit, M., CMMID COVID-19 working group, Pearson, C. A. B., Quilty, B. J., Kucharski, A. J., Gibbs, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0962-9 · Cited by 1,759 · cited 1×
“Age-stratified susceptibility values were drawn from literature estimates ( 13 ).”
Sex differences in immune responses that underlie COVID-19 disease outcomes
Takahashi, T., Ellingson, M. K., Wong, P., Israelow, B., Lucas, C., Klein, J., Silva, J., Mao, T., Oh, J. E., Tokuyama, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2700-3 · Cited by 1,459 · cited 1×
“However, other factors correlate with disease outcomes, such as treatment and healthcare access and comorbidities, which may correlate with factors like rural vs urban location, socioeconomic status, sex ( 41, 42 ), and race and ethnicity ( 43 ), that are not accounted for in this study.”
Why does COVID-19 disproportionately affect older people?
Mueller, A. L., McNamara, M. S., & Sinclair, D. A. (2020) · Aging · doi:10.18632/aging.103344 · Cited by 1,128 · cited 1×
“We evaluated the impact of vaccine prioritization strategies using an age-stratified SEIR model, because age has been shown to be an important correlate of susceptibility ( 12–14 ), seroprevalence ( 12,15 ), severity ( 16–18 ), and mortality ( 19,20 ).”
Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China
Zhang, J., Litvinova, M., Liang, Y., Wang, Y., Wang, W., Zhao, S., Wu, Q., Merler, S., Viboud, C., Vespignani, A., et al. (2020) · Science · doi:10.1126/science.abb8001 · Cited by 1,107 · cited 1×
“We evaluated the impact of vaccine prioritization strategies using an age-stratified SEIR model, because age has been shown to be an important correlate of susceptibility ( 12–14 ), seroprevalence ( 12,15 ), severity ( 16–18 ), and mortality ( 19,20 ).”
The Efficacy of Influenza Vaccine in Elderly Persons: A Meta-Analysis and Review of the Literature
Gross, P. A., Hermogenes, A. W., Sacks, H. S., Lau, J., & Levandowski, R. A. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-7-199510010-00008 · Cited by 1,100 · cited 1×
“COVID-19 vaccines may not be equally effective across age groups in preventing infection or transmission, a phenomenon known to affect influenza vaccines ( 23–26 ).”
Estimating the burden of SARS-CoV-2 in France
Salje, H., Tran Kiem, C., Lefrancq, N., Courtejoie, N., Bosetti, P., Paireau, J., Andronico, A., Hozé, N., Richet, J., Dubost, C.-L., et al. (2020) · Science · doi:10.1126/science.abc3517 · Cited by 1,038
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
Lumley, S. F., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T., Warren, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034545 · Cited by 940 · cited 2×
“Serostatus itself is an imperfect indicator of protection, and the relationship of prior infection, serostatus, and protection may change over time (10, 29,32,33).”
Govaert, T. M. E. (1994) · JAMA · doi:10.1001/jama.1994.03520210045030 · Cited by 867
Research works printed but not linked: 1
- K. E. Atkinson An Introduction to Numerical Analysis (Wiley 1989) chap. 2 pp. 56–58 second edn.
Cited by
Items 101–200 of 777
Nationwide rollout reveals efficacy of epidemic control through digital contact tracing
Elmokashfi, A. M., Sundnes, J., Kvalbein, A., Naumova, V., Reinemo, S.-A., Florvaag, P. M., Stensland, H. K., & Lysne, O. (2021) · Nature Communications · doi:10.1038/s41467-021-26144-8 · Cited by 42
“With Covid-19 expected to be endemic 30 , new virus variants 31 and a promising but lengthy vaccination campaign 32 , our findings suggest that digital contact tracing can greatly boost efforts to control the pandemic in the coming months.”
BackgroundA Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine
Kirwin, E. M., Rafferty, E., Harback, K., Round, J. A., & McCabe, C. J. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01037-2 · Cited by 37
Garg, A. K., Mittal, S., Padmanabhan, P., Desikan, R., & Dixit, N. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.776933 · Cited by 42
“With limited vaccine supplies, it becomes critical to identify dosing protocols that would maximize vaccine efficacy (3, 4).”
BackgroundForecasting new diseases in low-data settings using transfer learning
Roster, K. I. O., Connaughton, C., & Rodrigues, F. A. (2022) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2022.112306 · Cited by 41
“In that case, forecasts may be supplemented by results from mechanistic models, which enable simulations of public health interventions, such as prioritizing different vaccination strategies [34].”
BackgroundAn Economic Framework for Vaccine Prioritization
Akbarpour, M., Budish, E. B., Dworczak, P., & Kominers, S. D. (2023) · The Quarterly Journal of Economics · doi:10.1093/qje/qjad022 · Cited by 37
Vaccines and variants: Modelling insights into emerging issues in COVID-19 epidemiology
Caldwell, J. M., Le, X., McIntosh, L., Meehan, M. T., Ogunlade, S. T., Ragonnet, R. R., O’Neill, G. K., Trauer, J. M., & McBryde, E. S. (2021) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2021.07.002 · Cited by 40
“Given low vaccine efficacy, low coverage, or sustained transmission, prioritizing individuals >60 years of age should lead to the greatest reductions in hospitalisations and mortality [37], while targeting younger individuals should lead to the greatest reduction in incidence [14].”
Tran, T. N.-A., Wikle, N. B., Albert, E., Inam, H., Strong, E. R., Břinda, K., Leighow, S. M., Yang, F., Hossain, S., Pritchard, J. R., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02038-w · Cited by 35
Blockchain-based COVID vaccination registration and monitoring
Nabil, S. S., Pran, M. S. A., Haque, A. A. A., Chakraborty, N. R., Chowdhury, M. J. M., & Ferdous, M. S. (2022) · Blockchain Research and Applications · doi:10.1016/j.bcra.2022.100092 · Cited by 39
A COVID-19 vaccination model for Aotearoa New Zealand
Steyn, N., Plank, M. J., Binny, R. N., Hendy, S. C., Lustig, A. G., & Ridings, K. (2022) · Scientific Reports · doi:10.1038/s41598-022-06707-5 · Cited by 35
“This distinction is less important for determining optimal vaccine roll-out strategies [15], but we nonetheless test the effect of a “leaky vaccine” assumption in Supplementary Information sec 2.”
BackgroundMethodWang, X., Wu, H., & Tang, S. (2022) · Bulletin of Mathematical Biology · doi:10.1007/s11538-022-01064-w · Cited by 37
“Considering the limitation of initial supply of SARS-CoV-2 vaccines, five vaccine prioritization strategies are examined for the US using an age-stratified SEIR model[14].”
BackgroundMethodInfluentialWang, X., Li, Q., Sun, X., He, S., Xia, F., Song, P., Shao, Y., Wu, J., Cheke, R., Tang, S., et al. (2021) · BMC Public Health · doi:10.1186/s12889-021-10657-4 · Cited by 34
Evaluation of the United States COVID-19 vaccine allocation strategy
Islam, M. R., Oraby, T. F., McCombs, A., Chowdhury, M. M., Al-Mamun, M. A., Tyshenko, M. G., & Kadelka, C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259700 · Cited by 38
“The other two parameters, c 2 [4, 6] and k 2 [2, 16], describe the shape of the Hill function used to model the population-wide social-distancing level, which depends on the number of active cases (Eq 2).”
Using Constrained Optimization for the Allocation of COVID-19 Vaccines in the Philippines
Buhat, C. A. H., Lutero, D. S., Olave, Y. H., Quindala, K. M., Recreo, M. G. P., Talabis, D. A. S. J., Torres, M. C., Tubay, J. M., & Rabajante, J. F. (2021) · Applied Health Economics and Health Policy · doi:10.1007/s40258-021-00667-z · Cited by 33
“Ni − Ci , to further stretch the distribution of vaccines in many localities [26].”
BackgroundTargeted vaccination and the speed of SARS-CoV-2 adaptation
Gandon, S., & Lion, S. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2110666119 · Cited by 33
Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination
Paniskaki, K., Anft, M., Meister, T. L., Marheinecke, C. S., Pfaender, S., Skrzypczyk, S., Seibert, F. S., Thieme, C. J., Konik, M., Dolff, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.816220 · Cited by 34
Strategies for Vaccine Prioritization and Mass Dispensing
Lee, E. K., Li, Z. L., Liu, Y. K., & LeDuc, J. W. (2021) · Vaccines · doi:10.3390/vaccines9050506 · Cited by 32
“Some models partition the population according to age-groups [36], while others incorporate demographic information, and risk factors [37,38].”
Which Group Should be Vaccinated First?: A Systematic Review
Noh, E. B., Nam, H. K., & Lee, H. (2021) · Infection and Chemotherapy · doi:10.3947/ic.2021.0029 · Cited by 32
From Policy to Prediction: Forecasting COVID-19 Dynamics Under Imperfect Vaccination
Wang, X., Hao Wang, A., Ramazi, P., Nah, K., & Lewis, M. A. (2022) · Bulletin of Mathematical Biology · doi:10.1007/s11538-022-01047-x · Cited by 32
Blasioli, E., Mansouri, B., Tamvada, S. S., & Hassini, E. (2023) · Operations Research Forum · doi:10.1007/s43069-023-00194-8 · Cited by 39
“Some considerations are inevitable when developing models for optimal vaccine allocation, making sure to address equity in allocation between countries as well as disparities in accessing healthcare services [2].”
BackgroundInfluentialKayano, T., Ko, Y., Otani, K., Kobayashi, T., Suzuki, M., & Nishiura, H. (2023) · Scientific Reports · doi:10.1038/s41598-023-44942-6 · Cited by 32
“Published studies have indicated that prioritized vaccination for older people could minimize COVID-19 mortality if vaccines are not sufficiently available 24–28 .”
Comparative evaluation of behavioral epidemic models using COVID-19 data
Gozzi, N., Perra, N., & Vespignani, A. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2421993122 · Cited by 41
Mathematical modeling of spatio-temporal population dynamics and application to epidemic spreading
Winkelmann, S., Zonker, J., Schütte, C., & Conrad, N. D. (2021) · Mathematical Biosciences · doi:10.1016/j.mbs.2021.108619 · Cited by 31
The Ethics of Selective Mandatory Vaccination for COVID-19
Williams, B. (2021) · Public Health Ethics · doi:10.1093/phe/phab028 · Cited by 31
“Modelling studies have suggested that in this condition of scarcity, prioritizing the elderly for vaccination is most likely to minimize COVID-19 mortality (Hogan et al., 2020; Bubar et al., 2021; Moore et al., 2021).”
BackgroundOptimal vaccine allocation for COVID-19 in the Netherlands: A data-driven prioritization
Miura, F., Leung, K. Y., Klinkenberg, D., Ainslie, K. E. C., & Wallinga, J. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009697 · Cited by 30
“The maximum vaccine uptake was assumed to be 80% for all age groups, following previous modelling studies [13,16].”
BackgroundMethodResultInfluentialIyaniwura, S. A., Falcão, R. C., Ringa, N., Adu, P., Spencer, M., Taylor, M., Colijn, C., Coombs, D., Janjua, N. Z., Irvine, M. A., et al. (2022) · Epidemics · doi:10.1016/j.epidem.2022.100559 · Cited by 30
Collin, A., Hejblum, B. P., Vignals, C., Lehot, L., Thiébaut, R., Moireau, P., & Prague, M. (2023) · The International Journal of Biostatistics · doi:10.1515/ijb-2022-0087 · Cited by 31
Epidemiological Differences in the Impact of COVID-19 Vaccination in the United States and China
Makhoul, M., Chemaitelly, H. S., Ayoub, H. H., Seedat, S., & Abu-Raddad, L. J. (2021) · Vaccines · doi:10.3390/vaccines9030223 · Cited by 29
“Impact of vaccination prioritization by age was not assessed, as it was investigated in earlier studies [5,39].”
ResultZou, Y., Yang, W. H., Lai, J., Hou, J., & Lin, W. C. (2022) · Bulletin of Mathematical Biology · doi:10.1007/s11538-021-00958-5 · Cited by 30
“Due to the scarcity of vaccines, priority groups for vaccination have been discussed (Medlock and Galvani 2009; Bubar et al. 2021).”
Homophily impacts the success of vaccine roll-outs
Burgio, G., Steinegger, B., & Arenas, À. (2022) · Communications Physics · doi:10.1038/s42005-022-00849-8 · Cited by 31
Saldaña, F., & Velasco‐Hernández, J. X. (2021) · Royal Society Open Science · doi:10.1098/rsos.202240 · Cited by 29
Jarumaneeroj, P., Dusadeerungsikul, P. O., Chotivanich, T., Nopsopon, T., & Pongpirul, K. (2022) · Computers & Industrial Engineering · doi:10.1016/j.cie.2022.108031 · Cited by 28
“, 2008) or serological-based prioritization (Bubar et al., 2021), whose effectiveness is found to depend not only on the allocation of vaccines at strategic levels but also on the administration of such vaccines at operational levels.”
Microsimulation based quantitative analysis of COVID-19 management strategies
Reguly, I. Z., Csercsik, D., Juhász, J., Tornai, K., Bujtár, Z., Horváth, G., Keömley-Horváth, B. M., Kós, T., Cserey, G., Iván, K., et al. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009693 · Cited by 29
Modeling the Impact of Vaccination on COVID-19 and Its Delta and Omicron Variants
Wang, J., Chan, Y.-C., Niu, R., Wong, E. W. M., & van Wyk, M. A. (2022) · Viruses · doi:10.3390/v14071482 · Cited by 28
“Furthermore, [7,8] do not provide estimates of herd immunity thresholds for COVID-19.”
BackgroundDey, S., Kurbanzade, A. K., Gel, E. S., Mihaljevic, J. R., & Mehrotra, S. (2024) · Naval Research Logistics (NRL) · doi:10.1002/nav.22181 · Cited by 31
Hogan, A. B., Wu, S. L., Toor, J., Mesa, D. O., Doohan, P., Watson, O. J., Winskill, P., Charles, G. D., Barnsley, G., Riley, E. M., et al. (2023) · PLoS Medicine · doi:10.1371/journal.pmed.1004195 · Cited by 29
Kargar, B., MohajerAnsari, P., Büyüktahtakın, İ. E., Jahani, H., & Talluri, S. (2024) · Transportation Research Part E Logistics and Transportation Review · doi:10.1016/j.tre.2024.103494 · Cited by 27
Challenges of evaluating and modelling vaccination in emerging infectious diseases
Madewell, Z. J., Dean, N. E., Berlin, J. A., COPLAN, P. M., Davis, K. J., Struchiner, C. J., & Halloran, M. E. (2021) · Epidemics · doi:10.1016/j.epidem.2021.100506 · Cited by 31
Adaptive and optimized COVID-19 vaccination strategies across geographical regions and age groups
Molla, J., Chávez, A. P. D. L., Hiraoka, T., Ala-Nissilä, T., Kivelä, M., & Leskelä, L. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009974 · Cited by 28
“We consider an extension of the all-or-nothing model [2, 12] in order to take into account individual variations in immunity.”
Factors Affecting the Antibody Immunogenicity of Vaccines against SARS-CoV-2: A Focused Review
Cheng, Z. J., Xue, M., Zheng, P., Lyu, J., Zhan, Z., Hu, H., Zhang, Y., Zhang, X. D., & Sun, B. (2021) · Vaccines · doi:10.3390/vaccines9080869 · Cited by 31
“A highly effective transmissible blocking vaccine given to adults aged 20 to 49 that would minimize cumulative morbidity, while giving priority to adults aged 60 and older would have the lowest mortality rate [23].”
BackgroundCOVID-19 vaccine strategies for Aotearoa New Zealand: a mathematical modelling study
Nguyen, T., Adnan, M., Nguyen, B. P., de Ligt, J., Geoghegan, J. L., Dean, R. A., Jefferies, S., Baker, M. G., Seah, W. K. G., Sporle, A. A., et al. (2021) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2021.100256 · Cited by 29
“Bubar et al. 35 compared five vaccine strategies that allocate vaccine doses on ‘under 20’, ‘adults 20–49’, ‘adults 20 + ’, ‘adults 60 + ’, and ‘all ages’ in terms of the reduction of deaths and infections.”
Nguyen, L. K. N., Megiddo, I., & Howick, S. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009780 · Cited by 26
Age-Stratified COVID-19 Spread Analysis and Vaccination: A Multitype Random Network Approach
Chen, X., Zhu, G., Zhang, L., Fang, Y. M., Guo, L., & Chen, X. (2021) · IEEE Transactions on Network Science and Engineering · doi:10.1109/tnse.2021.3075222 · Cited by 26
COVID-19 deterministic and stochastic modelling with optimized daily vaccinations in Saudi Arabia
Omar, O. A. M., Alnafisah, Y., Elbarkouky, R. A., & Ahmed, H. M. (2021) · Results in Physics · doi:10.1016/j.rinp.2021.104629 · Cited by 25
“Many mathematical models have demonstrated their ability to predict daily infections and deaths with pinpoint accuracy [1,2].”
Suphanchaimat, R., Tuangratananon, T., Rajatanavin, N., Phaiyarom, M., Jaruwanno, W., & Uansri, S. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182010803 · Cited by 26
“In addition, the models used in vaccine prioritization studies always differ in details (assumptions, structures, and parameters, for instance), meaning that a direct contrast of outcomes across studies is impossible [31,32].”
BackgroundMethodChen, Y.-T. (2022) · Health Policy and Technology · doi:10.1016/j.hlpt.2022.100699 · Cited by 28
“[53] Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, Grad YH, et al.”
BackgroundKo, Y., Lee, J., Kim, Y.-J., Kwon, D., & Jung, E. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18126469 · Cited by 29
“introduced model-informed COVID-19 vaccine prioritization by age and serostatus [12].”
MethodFirst indication of the effect of COVID-19 vaccinations on the course of the outbreak in IsraelPreprint
De-Leon, H., Calderon‐Margalit, R., Pederiva, F., Ashkenazy, Y., & Gazit, D. (2021) · medRxiv · doi:10.1101/2021.02.02.21250630 · Cited by 25
“Another modelling study that compared different strategies in prioritizing vaccines (8), suggested”
BackgroundMathematical analysis of simple behavioral epidemic models
LeJeune, L., Ghaffarzadegan, N., Childs, L. M., & Saucedo, O. (2024) · Mathematical Biosciences · doi:10.1016/j.mbs.2024.109250 · Cited by 27
Behavioral responses to risk promote vaccinating high‐contact individuals first
Rahmandad, H. (2021) · medRxiv · doi:10.1002/sdr.1714 · Cited by 22
“(1) (BL for shorthand) supports vaccinating the elderly first to minimize total deaths and years of life lost (YLL), especially if COVID-19’s basic reproduction number (R0) is above 1.”
BackgroundA COVID-19 Epidemic Model Predicting the Effectiveness of Vaccination in the US
Webb, G. F. (2021) · Infectious Disease Reports · doi:10.3390/idr13030062 · Cited by 25
Preparing for a Pandemic: Accelerating Vaccine Availability
Ahuja, A., Athey, S. C., Baker, A., Budish, E. B., Castillo, J. C., Glennerster, R., Kominers, S. D., Kremer, M. R., Lee, J. N., Prendergast, C. J., et al. (2021) · National Bureau of Economic Research · doi:10.3386/w28492 · Cited by 24
Modeling the Impact of COVID-19 Vaccination in Lebanon: A Call to Speed-Up Vaccine Roll Out
Mumtaz, G. R., El‐Jardali, F., Jabbour, M., Harb, A., Abu-Raddad, L. J., & Makhoul, M. (2021) · Vaccines · doi:10.3390/vaccines9070697 · Cited by 25
“We did not assess the impact of vaccine prioritization by age as it was investigated in earlier studies [18, 35].”
BackgroundResultEffect of homophily and correlation of beliefs on COVID-19 and general infectious disease outbreaks
Kadelka, C., & McCombs, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0260973 · Cited by 23
The impacts of SARS-CoV-2 vaccine dose separation and targeting on the COVID-19 epidemic in England
Keeling, M. J., Moore, S., Penman, B. S., & Hill, E. M. (2023) · Nature Communications · doi:10.1038/s41467-023-35943-0 · Cited by 27
Mengüç, K., Aydın, N., & Ulu, M. (2023) · International Journal of Production Research · doi:10.1080/00207543.2023.2182151 · Cited by 23
“In the United States, Bubar et al. (2021) found that one vaccine that blocks transmission should be given priority in young adults (20–49 years) to minimise cumulative incidence and in people over 60 years of age to minimise mortality.”
Yang, C., Yang, Y., & Li, Y. (2021) · PLoS ONE · doi:10.1371/journal.pone.0261236 · Cited by 23
Prioritizing COVID-19 vaccination efforts and dose allocation within Madagascar
Rasambainarivo, F., Ramiadantsoa, T., Raherinandrasana, A. H., Randrianarisoa, S., Rice, B. L., Evans, M., Roche, B., Randriatsarafara, F. M., Wesolowski, A., & Metcalf, C. J. E. (2022) · BMC Public Health · doi:10.1186/s12889-022-13150-8 · Cited by 22
“The pro rata distribution of vaccines between regions or allocating doses according to the 259 regional distribution of older people outperform distribution according to numbers of cases (or 260 deaths) since all else equal, weighting by numbers of older individuals (which correlates with 261 number of individuals) ta…”
BackgroundWei, J., Matthews, P. C., Stoesser, N. E., Diamond, I. D., Studley, R., Rourke, E. D., Cook, D., Bell, J. I., Newton, J. N., Farrar, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31495-x · Cited by 26
Application of Traditional Vaccine Development Strategies to SARS-CoV-2
Rando, H. M., Lordan, R., Lee, A. J., Naik, A. S., Wellhausen, N., Sell, E., Kolla, L., Gitter, A., Greene, C. S., Bansal, V., et al. (2023) · mSystems · doi:10.1128/msystems.00927-22 · Cited by 24
Basciftci, B., Yu, X., & Shen, S. (2022) · Computers & Operations Research · doi:10.1016/j.cor.2022.106028 · Cited by 27
Expanding capacity for vaccines against Covid-19 and future pandemics: a review of economic issues
Athey, S. C., Castillo, J. C., Chaudhuri, E., Kremer, M. R., Gomes, A. S., & Snyder, C. M. (2022) · Oxford Review of Economic Policy · doi:10.1093/oxrep/grac037 · Cited by 22
Guerstein, S., Romeo-Aznar, V., Dekel, M., Miron, O., Davidovitch, N., Puzis, R., & Pilosof, S. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009319 · Cited by 22
Farina, M., & Lavazza, A. (2021) · International Journal of Public Health · doi:10.3389/ijph.2021.1604036 · Cited by 23
Ferreira, L. S., Canton, O., Lopes, R., Poloni, S., Sudbrack, V., Borges, M. E., Franco, C. F. J., Marquitti, F. M. D., de Moraes, J. C., Veras, M. A. D. S. M., et al. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009978 · Cited by 21
“[20] has shown that the outcome of these models do not differ substantially and the leaky model is simpler to understand and to implement.”
BackgroundAge-specific transmission dynamics of SARS-CoV-2 during the first 2 years of the pandemic
Boldea, O., Alipoor, A., Pei, S., Shaman, J. L., & Rozhnova, G. (2024) · PNAS Nexus · doi:10.1093/pnasnexus/pgae024 · Cited by 22
“…age and time and the contribution of different age groups to transmission (6, 7) may inform non-pharmaceutical interventions (8 – 12) like school-and non-school-based measures (13), while understanding of the age-specific hospitalization burden (14) underpins prioritization of vaccination (15, 16).”
Tsang, T. K., Sullivan, S. G., Huang, X., Wang, C., Wang, Y., Nealon, J., Yang, B., Ainslie, K. E. C., & Cowling, B. J. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae142 · Cited by 25
SARS-CoV-2: Cross-scale Insights from Ecology and Evolution
Snedden, C. E., Makanani, S. K., Schwartz, S. T., Gamble, A., Blakey, R. V., Borremans, B., Helman, S. K., Espericueta, L., Valencia, A., Endo, A., et al. (2021) · Trends in Microbiology · doi:10.1016/j.tim.2021.03.013 · Cited by 22
“Most models of disease transmission are based on the classification of individuals into susceptible (S), infectious (I), and recovered/immune (R) states (Figure I), though additional states are frequently included [26,27].”
How Artificial Intelligence and New Technologies Can Help the Management of the COVID-19 Pandemic
Barbieri, D., Giuliani, E., Prete, A. D., Losi, A., Villani, M., & Barbieri, A. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18147648 · Cited by 25
“used a mathematical model to compare age and serostatus-stratified prioritization strategies [41].”
MethodImai, N., Hogan, A. B., Williams, L. R., Cori, A., Mangal, T. D., Winskill, P., Whittles, L. K., Watson, O. J., Knock, E., Baguelin, M., et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16992.1 · Cited by 25
The Macroeconomics of Age-Varying Epidemics
Giagheddu, M., & Papetti, A. (2020) · European Economic Review · doi:10.1016/j.euroecorev.2022.104346 · Cited by 22
“The former objective s better achieved prioritizing the vaccination of the elderly, while the latter is better attained via prioritizing the vaccination of he young as shown in Bubar et al. (2021) and Buckner et al. (2021). Several countries have initially considered a combination f these principles in their vaccinati…”
BackgroundCohen, J. A., Stuart, R. M., Rosenfeld, K., Lyons, H. M., White, M. T., Kerr, C. C., Klein, D. J., & Famulare, M. (2021) · medRxiv · doi:10.1101/2021.05.31.21258018 · Cited by 22
Zhang, Y., Chen, H., Lv, J., Huang, T., Zhang, R., Zhang, D., Luo, L., Wei, S., Liu, X., Zhang, S., et al. (2022) · Vaccines · doi:10.3390/vaccines10071020 · Cited by 21
“Several previous studies have also provided similar advice [18,22].”
ResultAruffo, E., Yuan, P., Tan, Y., Gatov, E., Moyles, I. R., Bélair, J., Watmough, J., Collier, S., Arino, J., & Zhu, H. (2022) · BMC Public Health · doi:10.1186/s12889-022-13597-9 · Cited by 20
“While vaccination of young children was approved much later, some previous studies still considered younger age groups when defining the best vaccine rollout for minimizing infections, hospitalizations, and deaths [9, 24, 25].”
A COVID-19 model incorporating variants, vaccination, waning immunity, and population behavior
LaJoie, Z., Usherwood, T. R., Sampath, S. G., & Srivastava, V. (2022) · Scientific Reports · doi:10.1038/s41598-022-24967-z · Cited by 22
Efficiency in COVID-19 Vaccination Campaigns—A Comparison across Germany’s Federal States
Götz, G., Herold, D., Klotz, P.-A., & Schäfer, J. T. (2021) · Vaccines · doi:10.3390/vaccines9070788 · Cited by 20
“Despite the scarcity of vaccines, and subject to a prioritization of vulnerable and/or exposed individuals within the population [5,6], the policy goal is clear: roll out the available doses as quickly and efficiently as possible.”
BackgroundEgeren, D. V., Novokhodko, A., Stoddard, M., Tran, U., Zetter, B. R., Rogers, M. S., Joseph‐McCarthy, D., & Chakravarty, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-02148-8 · Cited by 25
Narrative Review of the COVID-19 Pandemic’s First Two Years in Italy
Beccia, F., Pilla, A. D., Causio, F. A., Federico, B., Specchia, M. L., Favaretti, C., Boccia, S., & Damiani, G. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192315443 · Cited by 20
“Then, the advent of vaccination and vaccination programs characterized the second year, with regional plans and the prioritization of administration by age group and at-risk categories, given the shortage of doses and organizational needs, favoring, to a certain extent, the stratification of the pandemic across the co…”
BackgroundFormulating human risk response in epidemic models: Exogenous vs endogenous approaches
LeJeune, L., Ghaffarzadegan, N., Childs, L. M., & Saucedo, O. (2025) · European Journal of Operational Research · doi:10.1016/j.ejor.2025.01.004 · Cited by 19
“Another example of exogenous modeling of risk response is by Bubar et al. (2021).”
Determinants of SARS-CoV-2 transmission to guide vaccination strategy in an urban area
Brüningk, S. C., Klatt, J., Stange, M., Mari, A., Brunner, M., Roloff, T. C., Seth-Smith, H. M. B., Schweitzer, M., Leuzinger, K., Søgaard, K. K., et al. (2022) · Virus Evolution · doi:10.1093/ve/veac002 · Cited by 22
“This finding is in agreement with previous results obtained across different countries (Bubar et al. 2021).”
ResultVoigt, A., Omholt, S. W., & Almaas, E. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263155 · Cited by 19
“It is a common observation that strategies which are highly effective at suppressing spread are not so effective at minimizing mortality, and vice versa [27–29].”
Sensitivity theorems of a model of multiple imperfect vaccines for COVID-19
Aguilar-Canto, F. J., de León, U. A.-P., & Avila-Vales, E. J. (2022) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2022.111844 · Cited by 19
Somekh, I., KhudaBukhsh, W. R., Root, E. D., Keinan‐Boker, L., Rempała, G. A., Simões, E. A. F., & Somekh, E. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac087 · Cited by 19
Jiang, Y., Cai, D., & Shi, S. (2021) · Infectious Disease Modelling · doi:10.1016/j.idm.2021.12.002 · Cited by 23
“In fact, COVID vaccination is considered to have a pivotal role in many pandemic exit strategies that are being considered (Bubar et al., 2021; Grif fi n et al., 2021; The Lancet Infectious).”
Petrizzelli, F., Guzzi, P. H., & Mazza, T. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.05.040 · Cited by 20
“However, considering the spread of COVID-19 and the production rates, there is a need for developing ad hoc prioritization strategies [6] that are also effective for subsequent pandemics.”
Emerging Landscape of Nanobodies and Their Neutralizing Applications against SARS-CoV-2 Virus
Feng, X., & Wang, H. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00042 · Cited by 19
Africa's preparedness towards COVID-19 vaccines: Demand and acceptability challenges
Hagan, J. E., Ahinkorah, B. O., Seidu, A., Ameyaw, E. K., & Schack, T. (2021) · Current Research in Behavioral Sciences · doi:10.1016/j.crbeha.2021.100048 · Cited by 19
The COVID-19 Vaccine Preference for Youngsters Using PROMETHEE-II in the IFSS Environment
Narayanamoorthy, S., Pragathi, S., Parthasarathy, T. N., Kalaiselvan, S., Kureethara, J. V., Saraswathy, R., Nithya, P., & Kang, D. (2021) · Symmetry · doi:10.3390/sym13061030 · Cited by 18
“[3] had proposed the vaccine prioritization with an informable approach to reduce the death rate and cumulative infection for adults aged 20 to 49.”
BackgroundDembiński, Ł., Martins, M. V., Huss, G., Grossman, Z., Barak, S., Magendie, C., del Torso, S., Dornbusch, H. J., Mazur, A., Albrecht, K., et al. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.721257 · Cited by 18
Gao, S., & Wang, H. (2021) · Future Generation Computer Systems · doi:10.1016/j.future.2021.09.028 · Cited by 18
The heterogeneous mixing model of COVID-19 with interventions
Duan, M., & Jin, Z. (2022) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2022.111258 · Cited by 15
A missing behavioural feedback in COVID-19 models is the key to several puzzles
Rahmandad, H., Xu, R., & Ghaffarzadegan, N. (2022) · BMJ Global Health · doi:10.1136/bmjgh-2022-010463 · Cited by 18
Handel, A., Miller, J. C., Ge, Y., & Fung, I. C. (2023) · Disaster Medicine and Public Health Preparedness · doi:10.1017/dmp.2023.203 · Cited by 18
“8 11 However, sustaining strong NPI for a potentially long period of time is not always feasible.”
BackgroundModeling geographic vaccination strategies for COVID-19 in Norway
Chan, L. Y. H., Rø, G., Midtbø, J. E., Ruscio, F. D., Watle, S. V., Juvet, L. K., Littmann, J., Aavitsland, P., Nygård, K. M., Berg, A. S., et al. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011426 · Cited by 18
“The trade-off between infections and deaths is mainly due to the age-specific contact and risk as shown in several studies on age prioritization [16–27].”
Inference of epidemic dynamics in the COVID-19 era and beyond
Cori, A., & Kucharski, A. J. (2024) · Epidemics · doi:10.1016/j.epidem.2024.100784 · Cited by 20
Deterministic optimal control compartmental model for COVID-19 infection
Afful, B. A., Safo, G. A., Marri, D., Okyere, E., Ohemeng, M. O., & Kessie, J. A. (2025) · Modeling Earth Systems and Environment · doi:10.1007/s40808-024-02183-0 · Cited by 20
Bello‐Chavolla, O. Y., Antonio‐Villa, N. E., Fernández‐Chirino, L., Guerra, E. C., Fermín‐Martínez, C. A., Márquez‐Salinas, A., Vargas‐Vázquez, A., & Bahena-López, J. P. (2021) · PLoS ONE · doi:10.1371/journal.pone.0256447 · Cited by 18
The Global Health Security Index is not predictive of vaccine rollout responses among OECD countries
Khalifa, B. A. A., Abbey, E. J., Ayeh, S. K., Yusuf, H. E., Nudotor, R. D., Osuji, N., Khan, S., Nosakhare, E., Oduwole, M. O., Salia, E. L., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.09.034 · Cited by 18
Aylett-Bullock, J., Gilman, R. T., Hall, I., Kennedy, D. S., Evers, E. S., Katta, A., Ahmed, H., Fong, K. J., Adib, K., Ariqi, L. A., et al. (2022) · BMJ Global Health · doi:10.1136/bmjgh-2021-007822 · Cited by 18
A mathematical model reveals the influence of NPIs and vaccination on SARS-CoV-2 Omicron Variant
Wang, B.-G., Wang, Z., Wu, Y. Y., Xiong, Y., Zhang, J., & Ma, Z. (2022) · Nonlinear Dynamics · doi:10.1007/s11071-022-07985-4 · Cited by 19
“[4] found a highlymitigated spread during vaccine rollout.”
BackgroundMethodReframing Optimal Control Problems for Infectious Disease Management in Low-Income Countries
Igoe, M., Casagrandi, R., Gatto, M., Hoover, C. M., Mari, L., Ngonghala, C. N., Remais, J. V., Sanchirico, J. N., Sokolow, S. H., Lenhart, S., et al. (2023) · Bulletin of Mathematical Biology · doi:10.1007/s11538-023-01137-4 · Cited by 22
“Due to systematic pervasive nonlinearities and heterogeneities underlying infectious disease transmission at the population level, epidemiological modeling is a key tool for exploring the potential impact of candidate intervention strategies (Bubar et al. 2021).”
Background
Metadata
- Authors
- Bubar, K. M., Reinholt, K., Kissler, S. M., Lipsitch, M., Cobey, S., Grad, Y. H., & Larremore, D. B.
- Affiliations
- University of Colorado Boulder (US)
- Harvard University (US)
- University of Chicago (US)
- Corresponding author
- Bubar, Kate M.
- Larremore, Daniel B.
- ORCID
- Venue
- Science
- Published
- 2021-02-26
- Volume
- 371
- Issue
- 6532
- Pages
- 916-921
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7963218
- OpenAlex
- W3123021790
- Cited by
- 775
- References
- 45
- Citations by year
- 2026: 32 · 2025: 56 · 2024: 87 · 2023: 109 · 2022: 222 · 2021: 261
- FWCI
- 65.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Knowledge@UChicago (University of Chicago) (submittedVersion, cc-by-nc-nd)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
- ImmPort
- University of Chicago (cc-by)
- Funders
- National Institutes of Health (3U24GM132013-02S2)
- Morris-Singer Fund
- Topics
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- COVID-19 vaccine prioritization, SARS-CoV-2, serostatus, serological testing, transmission-blocking vaccine, vaccine inequity, cumulative incidence, mortality, years of life lost, naturally acquired immunity, vaccine supply
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.